The Outcome of Cirrhotic Patients with Ascites Is Improved by the Normalization of the Serum Sodium Level by Tolvaptan

Objective Hyponatremia is frequently observed in patients with decompensated liver cirrhosis and it is also related to a poor prognosis. The vasopressin V2-receptor antagonist tolvaptan is used to treat cirrhotic patients with ascites and increases the serum sodium (Na) level. In this study, we inve...

Full description

Saved in:
Bibliographic Details
Published in:Internal Medicine 2017/11/15, Vol.56(22), pp.2993-3001
Main Authors: Kogiso, Tomomi, Kobayashi, Mutsuki, Yamamoto, Kuniko, Ikarashi, Yuichi, Kodama, Kazuhisa, Taniai, Makiko, Torii, Nobuyuki, Hashimoto, Etsuko, Tokushige, Katsutoshi
Format: Article
Language:English
Subjects:
Aged
Antidiuretic Hormone Receptor Antagonists - therapeutic use
Ascites
Ascites - complications
Benzazepines - therapeutic use
Brain natriuretic peptide
brain natriuretic peptide (BNP)
Cirrhosis
Female
Humans
Hyponatremia
Hyponatremia - complications
Hyponatremia - drug therapy
Internal medicine
Japan
Liver
Liver cirrhosis
Liver Cirrhosis - complications
Male
Medical prognosis
Middle Aged
Original
Patients
Prognosis
Retrospective Studies
Sodium
Sodium - blood
Survival
Tolvaptan
Treatment Outcome
Vasopressin
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective Hyponatremia is frequently observed in patients with decompensated liver cirrhosis and it is also related to a poor prognosis. The vasopressin V2-receptor antagonist tolvaptan is used to treat cirrhotic patients with ascites and increases the serum sodium (Na) level. In this study, we investigated (i) whether or not correction of the Na level improves the prognosis of cirrhotic patients with ascites and (ii) predictors of normalization of the serum Na level after tolvaptan therapy. Methods This was a single-center retrospective study. A total of 95 Japanese cirrhotic patients (60 men, median age 63 years) were enrolled and received tolvaptan orally after hospitalization for ascites treatment. The serum Na level was monitored during the period of tolvaptan treatment. The laboratory data and survival rates of patients who achieved serum Na levels of
ISSN:0918-2918
1349-7235
DOI:10.2169/internalmedicine.9033-17